Amundi Revance Therapeutics, Inc. Transaction History
Amundi
- $275 Billion
- Q4 2024
A detailed history of Amundi transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Amundi holds 228 shares of RVNC stock, worth $585. This represents 0.0% of its overall portfolio holdings.
Number of Shares
228Holding current value
$585% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RVNC
# of Institutions
219Shares Held
77.6MCall Options Held
2.18MPut Options Held
5.27M-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA5.94MShares$15.3 Million9.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$14.5 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I05.1MShares$13.1 Million0.78% of portfolio
-
Fil LTD Hamilton, D04.2MShares$10.8 Million0.01% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...